Humacyte (NASDAQ:HUMA) Receives "Buy" Rating from D. Boral Capital

D. Boral Capital restated their buy rating on shares of Humacyte (NASDAQ:HUMA - Free Report) in a research report sent to investors on Wednesday,Benzinga reports. The brokerage currently has a $25.00 price target on the stock.

Several other equities analysts have also issued reports on HUMA. Wall Street Zen lowered Humacyte from a "hold" rating to a "sell" rating in a research note on Friday, July 18th. HC Wainwright assumed coverage on Humacyte in a report on Wednesday, May 14th. They set a "buy" rating and a $4.00 target price for the company. Finally, Benchmark decreased their price target on Humacyte from $17.00 to $14.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $11.71.

Humacyte Price Performance

HUMA traded down $0.14 during trading on Wednesday, reaching $2.53. 4,157,702 shares of the company traded hands, compared to its average volume of 3,939,077. The firm has a fifty day simple moving average of $2.42 and a 200 day simple moving average of $2.69. Humacyte has a 12-month low of $1.15 and a 12-month high of $9.79. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.28 and a current ratio of 3.68. The company has a market cap of $392.45 million, a P/E ratio of -3.67 and a beta of 1.89.

Humacyte (NASDAQ:HUMA - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.09. The company had revenue of $0.52 million during the quarter, compared to the consensus estimate of $0.46 million. On average, equities analysts forecast that Humacyte will post -1.27 EPS for the current year.

Institutional Investors Weigh In On Humacyte

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Columbia Advisory Partners LLC purchased a new stake in Humacyte during the first quarter worth $27,000. Lazari Capital Management Inc. purchased a new stake in Humacyte during the second quarter worth $27,000. Vanguard Personalized Indexing Management LLC purchased a new stake in Humacyte during the second quarter worth $30,000. Valeo Financial Advisors LLC purchased a new stake in Humacyte during the second quarter worth $32,000. Finally, Hamilton Lane Advisors LLC acquired a new position in shares of Humacyte in the first quarter worth $37,000. Institutional investors and hedge funds own 44.71% of the company's stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.